Table 2.
Baseline and day 5 comparisons: primary and relevant secondary outcome measures
| Active (n = 19) | Placebo (n = 17) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 0 | Day 5 | Day 0 | Day 5 | |||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| NPI hallucinations subscale | 4.42 | 2.80 | 2.84 | 1.74 | 4.47 | 3.16 | 3.12 | 3.31 |
| CAMCOG | 60.05 | 22.92 | 59.00 | 27.23 | 58.24 | 21.39 | 55.12 | 22.85 |
| MMSE | 18.16 | 6.56 | 17.42 | 6.58 | 17.88 | 6.06 | 15.24 | 6.98 |
| CAF | 6.32 | 3.92 | 2.95 | 3.32 | 5.65 | 2.55 | 2.65 | 2.62 |
| ODFAS | 4.58 | 3.39 | 3.58 | 3.04 | 4.71 | 2.97 | 2.71 | 3.48 |
| TMS phosphene threshold (% output) | 73.69 | 21.83 | 84.31 | 23.15 | 78.88 | 27.94 | 89.65 | 16.33 |
| CGI-I | N/A | 3.42 | 1.26 | N/A | 3.35 | 0.93 | ||
SD standard deviation, NPI Neuropsychiatric Inventory, CAMCOG Cambridge Cognitive Examination, MMSE Mini Mental State Examination, CAF Clinical Assessment of Fluctuation, ODFAS One Day Fluctuation Scale, TMS transcranial magnetic stimulation, N/A not applicable, CGI-I Clinical Global Impression Scale (Improvement)